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A B S T R A C T
The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to
urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering
targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic
platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing
on nanomedicine that we take issue with Prof Park's recent editorial published in the Journal of Controlled
Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative
clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of
Controlled Release, 2019; 305, 221–222 [1]. We, the ETPN (European Technology Platform on Nanomedicine)
[2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval
of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine
field is concretely able to design products that overcome critical barriers in conventional medicine in a unique
manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of
action, and therefore make a difference in patients lives. Furthermore, the>400 nanomedicine formulations
currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery),
alone or in combination with other key enabling technologies to the market, including biotechnologies, mi-
crofluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT
(information & communication technologies) more generally. However, we agree with Prof. Park that “ it is time
to examine the sources of difficulty in clinical translation of nanomedicine and move forward “. But for reaching this
goal, the investments to support clinical translation of promising nanomedicine formulations should increase,
not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a
common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce
the current fragmentation of the standardization and regulatory body landscape. We should also promote a
strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost so-
lution to answer unmet medical needs and help the most promising innovative projects of the field to get better
and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years.
All actions should be taken with a clear clinical view in mind, “ without any fanfare”, to focus “on what matters in
real life”, which is the patient and his/her quality of life.
This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further ex-
panding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transfor-
mation of its great potential into tangible medical breakthroughs.
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1. Introduction
For decades the field of nanomedicine has promised to revolutionize
treatment outcomes for millions of patients. Has nanomedicine suc-
ceeded in meeting the initial expectations, making a real difference for
patients or is it still only delivering “lofty promises” of what “we hope it
might do someday”? In his editorial in the Journal of Controlled Release
[1], Prof. Park argues that the field of nanomedicine has been clearly
overrated, that it was overly focused on cancer therapy and that its
promises probably never will be realized. Based on these conclusions,
he suggests that the massive resources, time and financial investments
allocated to the field of nanomedicine should be refocused on other
priorities. It may be true that the publicly funded research investment
in the field is decreasing. For example, the US National Cancer Institute
(NCI) recently announced that, after 15 years, it will stop funding the
Centers of Cancer Nanotechnology Excellence (CCNEs). But the reason
for setting aside this funding mechanism was not the failure of the
nanomedicine field. On the contrary, the program was supposed to only
support emerging technologies, while nanomedicine is now considered
resilient enough to compete in other standard funding mechanisms.
Moreover, Prof. Grodzinski in response to Park, pointed out that the
CCNEs program was very successful, not only producing>3400 na-
nomedicine publications, but also generating concrete results, such as
the creation of> 100 start-up companies, and products entering>30
clinical trials in the US [3]. The Nanomedicine and Nanoscale Delivery
(NND) focus group of the Controlled Release Society (CRS) also recently
joined the discussion, arguing in favor of the solid progresses made by
nanomedicine [4].
The debate is open: are we at the beginning of the end of the na-
nomedicine hype, as suggested by Prof. Park, or are we just at the end of
the beginning which will guide nanomedicine into a new, more mature
phase? To answer this question, we propose to first proceed as de-
scribed in the citation used by Prof. Park himself: “Innovators who seek
to revolutionize and disrupt an industry must tell investors the truth about
what their technology can do today, not just what they hope it might do
someday.” We will argue in section one, how, in our opinion, nano-
medicine has already made a concrete difference in the treatment of
cancer and of other diseases. Then, in section two we will discuss the
bottlenecks that are still delaying nanomedicine's efficient translation
into the clinic, we will describe the main on-going European and in-
ternational initiatives to sustain the field alone or in combination with
other key enabling technologies (KETs). Finally, we will conclude on
the potential role that European infrastructures may play in the future,
notably within the framework of the upcoming Work Programme
Horizon Europe led by the European Commission (E.C.).
2. Section one: How nanomedicine is improving therapeutic
outcomes
It is very often claimed that nanomedicine failed to meet the initial
expectations in drug delivery, since less than 1% of the active phar-
macological ingredient (API) is locally released, e.g. in cancer treatment
in the tumoral tissues [5,6]. As pointed out by Scott Mc-Neil, former
Director of the Nanotechnology Characterization Laboratory (NCL) of
the NCI, the average amount of the API delivered locally may not be the
only parameter to judge the success of nanomedicine in cancer therapy,
since other pharmacological parameters, as peak drug concentration,
clearance rate and half time elimination may be significantly improved,
increasing the therapeutic outcome and also reducing side effects [7].
More importantly, the nanomedicine success cannot be judged only by
considering the delivered dose, since nanoparticles are not acting only
as passive drug carriers. In the last three years, three new formulations
were approved, Vyxeos, Onpattro and Hensify, clearly demonstrating
that a new generation of nanomedicine formulations has successfully
reached the market, opening new clinical perspectives based on their
unique physico-chemical properties.
3. The new generation of nanomedicine who made it to the
market
Currently more than 50 nanomedicine formulations have been ap-
proved for clinical use, as recently reviewed by multiple authors
[8–10]. These marketed nanomedicine formulations are approved for
cancer treatment, iron-replacement therapies, anesthetics, fungal
treatments, macular degeneration, and for the treatment of genetic rare
diseases [8]. Nano/microparticle imaging agents have also been in-
cluded in the statistics. The majority of approved NP classes are re-
presented by liposomes, iron colloids, protein-based NP, nano-emul-
sions, nanocrystals and metal oxide nanoparticles. The three new
formulations mentioned in the previous section, not only show that the
number of formulations approved are steadily increasing (Fig. 1), but
that new generations of nanomedicine are now reaching the market.
Vyxeos was approved in 2017 by the FDA for the treatment of acute
myeloid leukemia [11]. It allows the simultaneous delivery of two
drugs, cytarabine and daunorubicin, at a synergic fixed 5:1 ratio to
increase treatment efficacy with a lower cumulated dose. Due to dif-
ferential pharmacodynamics and biodistribution of drugs, a temporal
and spatial controlled delivery of this optimal ratio cannot be reached
by any other approach than by the encapsulation of the chosen mix of
drugs in a nano-object. It is easy to envision that such a success will be
reproduced with various drug combinations.
In 2018 Onpattro, the first lipid-based nanoformulation en-
capsulating siRNA, was approved for the treatment of transthyretin
amyloidosis [12], a rare disease. This approval is a great achievement,
nanomedicine being the first technology platform answering the needs
of nucleic acid delivery and finally making it available for patients.
Indeed, nucleotide-based drugs have an enormous therapeutic potential
but pose specific delivery challenges. In fact, nucleotides are rapidly
degraded in vivo and have little or no possibility to reach the target
region. Furthermore, they are negatively charged and uptake into cells
is electrostatically hindered. Hence, nucleotide drugs need both pro-
tection and a trojan horse to enter cells. The design of Onpattro com-
bines an efficient encapsulation of siRNA with prevention of its de-
gradation in vivo but also with the ability to perform endosomal escape
and delivery of siRNA within the cell cytoplasm. Considering the high
number of ongoing clinical trials based on nanomedicines en-
capsulating nucleic acids, including mRNAs, several new products will
be expected to reach the market in the near future. The current global
Covid-19 pandemic highlights that a vaccine, based on mRNA en-
capsulation in lipid-based nanoparticles, could now be developed with
unprecedented speed. Importantly, the therapeutic potential of mRNA
is vastly larger, and can provide solutions in multiple areas including
cancer vaccines and immune activation, in-body production of patients'
Fig. 1. Evolution of the approved nanomedicine formulations (cumulative
number/year). First year of approval reported for formulations approved by
multiple agencies (e.g. EMA and FDA).
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own therapeutic antibodies, protein replacement therapies and re-
generative medicine. Importantly, delivery of nucleic acids could be
used for any kind of permanent gene therapy of, conceivably, any ge-
netic disorder by encoding of the CRISPR/Cas9 complex [13]. There-
fore, we believe that Onpattro is only the very beginning of a paradigm
shift in the treatment of various therapeutic areas including oncology,
but also rare diseases, genetic or infectious diseases.
Nanomedicine cannot be considered simply as a drug delivery
system anymore since nanomaterials themselves may become the active
therapeutic ingredient. Nowadays, radiotherapy's efficacy is limited by
the tolerance of normal tissues adjacent to the tumor which reduces the
energy dose that can be administered safely the patient.
Nanotechnologies have created a new profile of material interactions
with cell biology. The use of a new class of radiation-enhancing nano-
particles could be a breakthrough approach for the local treatment of
solid tumors that are treated with radiotherapy. NBTXR3 is a first-in-
class nanoparticle composed of functionalized crystalline hafnium
oxide (HfO2). NBTXR3 nanoparticles were chosen for clinical devel-
opment because of their excellent ratio for x-ray absorption and ac-
ceptable safety. Once activated by ionizing radiation, NBTXR3 ad-
ministered intratumorally yields a cell-localized high energy deposit
and increased cell death compared with the same dose of radiation
alone, without adding toxicity to the surrounding tissues. This in-
novative approach proposes to broaden the therapeutic window of ra-
diation therapy by opening the possibility to bring physics at the heart
of the cells without changing radiotherapy practice. NBTXR3 obtained
its CE mark for the treatment of locally advanced soft tissue sarcoma in
2019 and the results from its phase 2–3 clinical trial were recently
published [14].
Other examples of the difference made by nanomedicine can be
found in liposomal marketed products in various therapeutic areas
[15]. The final aim of this paper is not to provide an exhaustive list of
products, but rather to highlight and focus on some of them, e.g. Vi-
sudyne, a liposomal formulation of verteporin, used in the treatment of
age-related macular degeneration (AMD) by photodynamic therapy
[16]. Encapsulation of verteporin is required since this molecule un-
dergoes self-aggregation in aqueous medium, limiting its bioavail-
ability. Ocular delivery is very challenging due to the presence of bio-
logical barriers (cornea, aqueous humor, etc.) which reduce the
bioavailability of topically or intraocularly administered therapeutic
agents. This situation demands frequent therapeutic agent administra-
tion which could limit the treatment especially for invasive intra-ocular
administration which can cause intraocular bleeding associated with
pain and discomfort that results in poor patient compliance. This de-
monstrates that nanomedicine has also made a difference in this ther-
apeutic area by offering the possibility to improve therapeutic agents'
bioavailability for intraocularly and topically administered drugs and
sustained drug release which reduces the frequency of drug adminis-
trations. Such benefits explain why there are already 10 nanomedicine-
based products marketed for ocular treatment [17].
Imaging also benefits from nanomedicine's properties. For example,
Magtrace is made of magnetic iron nanoparticles enable tracing of the
sentinel node in breast cancer without the use of radiomarkers, re-
sulting in a more efficient biopsy and detection of cancer cell migration
[18].
4. Who's next? Innovative formulations in pre-clinical and clinical
development
By analyzing the active or recruiting clinical trials in the
clinicaltrials.gov database we were able to identify 409 clinical trials
focusing on therapy and diagnostics involving nanomedicines. From the
beginning of 2018, more than 247 new clinical trials (active or re-
cruiting) have been started. Interestingly, in May 2020 at least 3 trials
were already started on vaccines for COVID-19 based on lipid-based
nanoparticles and this number will probably increase significantly in
the upcoming months. The most common formulations under in-
vestigation are still liposomes and protein based-nanoparticles, e.g.
Fig. 2. Nanoparticle classes investigated in ongoing clinical trials. The analysis was performed on 409 clinical trials from 2008 to 2020 (active, ongoing or re-
cruiting), identified in the clinicaltrials.gov database in May 2020. Search limited to trials identified with the following keywords: nanoparticle, liposome, liposomal,
lipid, vaccine, micelle, nanocrystal, virus like particle, silica particle, iron oxide, extracellular vesicle, dendrimer, nanobubble, lipoplex, gold nanoparticle. These
keywords were used alone or in association with other diseases or technologies specific keywords: COVID-19, mRNA, nucleic acid, cancer. Only trials using na-
noparticles were selected, eliminating doubloons arising from multiple searches. Repartition of nanoparticle types is presented for all ongoing clinical trials, for
cancer related applications (65% of the total) and for all applications outside oncology (35% of the total). (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
M. Germain, et al. Journal of Controlled Release 326 (2020) 164–171
166
Nab-paclitaxel/Abraxane, but since 2015 the number of other types of
nanomedicines reaching clinical testing has drastically increased with
new innovative concepts such as lipid-based nanoparticles for nucleic
acid delivery or metal oxides as radio-enhancers. Multiple trials are also
ongoing on polymeric nanoparticles, virus like particles, and micelles,
as represented in Fig. 2.
Even if nanomedicine is still highly focused on oncology, there is a
clear shift towards other clinical applications: while clinical trials for
cancer treatments remain above 50%, the number of clinical trials is
increasing in other indications including pain treatment, infection, and
vaccination. Furthermore, new indications/areas for treatment are
emerging encompassing diseases related to neural system diseases, eye
diseases and genetic diseases (Fig. 3).
5. The direction of cancer nanomedicine
65% of currently ongoing clinical trials are focused on cancer ap-
plications. To beat cancer, nanomedicine can offer great contributions
for better treatments and early diagnosis. It is important to stress that
even if the main goal remains to reduce or eradicate cancer, it is equally
important to improve the quality of life of patients during treatment,
helping to reduce the, often devastating, side effects. This is also where
nanomedicine can significantly contribute. Nanomaterial's potential to
deliver drugs locally, ensuring the therapeutic outcome by also redu-
cing side effects is thus very important in cancer applications [5]. In this
perspective, anti-cancer vaccines and personalized immuno-therapy
(nucleic acids-based technologies) can notably be developed by nucleic
acids-based technologies encapsulated in nanoparticle drug delivery
systems. Multiple clinical trials are currently ongoing on lipid-based
nanoparticles and on lipoplexes. Radio-enhancers like NBTXR3, could
be a revolutionary concept for treating solid tumors, by locally en-
hancing the delivered dose of radiation. Stimuli-responsive nano-car-
riers with hyperthermia, are another innovative concept explored in
clinical trials with the same purpose. For example, Thermodox, a heat
sensitive liposome loaded with doxorubicin [19], is under clinical in-
vestigation in the OPTIMA Phase III Study for Primary Liver Cancer in
combination with hyperthermia. In this clinical application, the com-
bination of a stimuli-responsive nano-carrier with hyperthermia treat-
ment, would allow a better temporal and spatial control of drug release,
improving the therapeutic outcome with a lower dose.
Nanomedicine can also support early cancer diagnosis by providing
ultrasensitive contrast agents. Several examples of nano-sized systems
for diagnostic are currently investigated in clinical trials, including iron
oxide nanoparticles for PET/MRI, and liposome/nanoparticle [18]
mediated delivery of contrast agents (99Tc or 111In as examples) to be
used in scintigraphy, SPECT or PET analysis.
6. Nanomedicine is not only focusing on cancer
Among the trials identified, 35% are investigating the use of na-
nomedicine for other clinical applications than cancer, demonstrating
that nanomedicine could make a difference in other therapeutic areas,
such as the central nervous system (CNS). Based on their unique phy-
sico-chemical properties (e. g. size, targeting agent coupling), nano-
medicines are able to act on / pass through the blood brain barrier
(BBB) and deliver the treatment more efficiently within the CNS.
Tailored nanomedicines can pass through the BBB via transcytosis or
endocytosis. Relevant preclinical results were obtained in various an-
imal models of brain diseases as gliomas [20], Huntington's [21], Alz-
heimer's [22–24] or neurometabolic diseases [25–27]. Strategies based
on transcytosis will typically give access to CNS delivery of small mo-
lecules but also nucleic acids or proteins via systemic and non-invasive
administration [28]. Also, there is ongoing research to modulate nerve
electrical activity or stimulate neural growth using gold nanoparticles
combined with laser activation [29]. Such approaches open opportu-
nities for the treatment of neurodegenerative diseases such as Parkin-
son's or Alzheimer's disease.
Furthermore, nanomedicine can become a key player in cross-sec-
toral and cross-technological solutions for healthcare. The unique
properties of nanoparticles (electrical, mechanical, acoustic, optical)
open new opportunities when combined with other technologies in
health. Some examples of cross-technological solutions have been cited
above. Furthermore, sensors should also be mentioned since their sen-
sitivity, speed and miniaturization may be improved by nanomedicine.
Such nanosensors will be suitable for more sensitive biomarker detec-
tion in a large panel of diseases (e. g. cancer, CNS and infectious dis-
eases). A review of Munawar et al. gives a good overview of the po-
tential of nanoparticles for nanosensors [30]. Typical applications of
nanosensors are found in the monitoring and control of pandemics and
plagues. There are now diagnostic tools that have been approved for
diseases such as Ebola and the Zika virus, which had the potential to
develop into global pandemics without nanotechnology-based pro-
ducts.
Fig. 3. Categorization of clinical trials based on nanomedicine formulation per indication: A) analysis on all the 409 trials and b) repartition per year in the 2016-
May 2020 period (333 trials). The analysis was performed on 409 clinical trials (active, ongoing or recruiting), identified in the clinicaltrials.gov database in May
2020. Search limited to trials identified with the following keywords: nanoparticle, liposome, liposomal, lipid, vaccine, micelle, nanocrystal, virus like particle, silica
particle, iron oxide nanoparticle, extracellular vesicle, dendrimer, nanobubble, lipoplex, gold nanoparticle. These keywords were used alone or in association with
other diseases or technologies specific keywords: COVID-19, mRNA, nucleic acid, cancer. Only trials using nanoparticles were selected, eliminating doubloons arising
from multiple searches. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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7. Nanomedicine: A platform for designing better medical
solutions
One major advantage of nanomedicines as designed objects over
other medicinal products is their high level of uncoupling between their
functional requirements (therapeutic effect & targeted delivery for in-
stance) and their design parameters (nanoparticle & drug for instance),
as could be described by the general theory of axiomatic design by Nam
P. Suh in the 1990's [31]. In other terms, a very interesting feature of
nanomedicines is to offer the characteristics of a generic platform in
which modules can be replaced, improved or re-designed without the
need to re-design the whole product from the beginning every time its
function needs to evolve. For instance, by keeping the same nano-
particle structure, but only changing the drug it carries, any other
therapeutic agents inside the particle or through fine tuning of the
coating of the particle, one can adapt the product to new applications or
subtypes of patients with the same disease, with better efficiency, and
while keeping some advantages inherent with the core particle itself.
Re-design of the whole product could also be done by functions un-
coupling in two distinct nanoparticles. Decreasing the notion of com-
promise between the required physico-chemical properties allows a
more efficient delivery of these functions improving the treatment
benefit / risk ratio [32]. This is indeed not the case for small organic
molecules & biologicals that need to go through a high number of
constraints for each new application. Answering these new constraints
require modifications in the drug design to optimize a specific function
but such modifications may also lead to degradation of other functions
in the same time. Indeed, each new nanomedicine has to follow a full
clinical development and no specific regulation at this stage is available
for them. Still, despite nanomedicines are often regulated as drugs, they
are different from classical drugs. As complex manufactured objects
offering tunable functions that can interact at sub-cellular level, nano-
medicines are platforms to design & deliver better medical solutions,
with personalized treatment capacities.
8. Nanomedicine: Clinical success rate
We have described in the last paragraphs examples of concrete
outcomes of the nanomedicine field and new exciting products to come.
But what is the average approval rate of nanomedicines compared to
classical drugs? Is there a difference in different fields, e.g. in oncology
vs other clinical applications?
He et al. calculated the success rate of nanomedicine formulations in
oncology for the different clinical phases [33]. They showed that the
success rate of nano-enabled cancer drugs in phase 1 is 94%, and this is
attributed to their good safety profile often couple to the improved
pharmacokinetic for the drug. Phase 2 and 3 success rates are respec-
tively of 48 and 14%. With an estimated total success rate from phase 1
to approval of 6%; thus, nanomedicines perform better than conven-
tional drugs in oncology, which have a success rate of 3.4 [34]. How-
ever, Prof. Park is right in saying that nanomedicine has been mainly
focused on cancer, and that the clinical outcome for other clinical ap-
plications has been poor. Why is it that, outside of oncology, only a few
nanomedicines reach clinical trials and market approval? We need to
enable and support clinical development of new promising formulations
for diseases that is not related to oncology [35]. But what should we do
to support the entry of new promising formulations of nanomedicines
into clinical trials?
9. Section two: Addressing the gaps to accelerate nanomedicine
translation into the clinic
The difficulties in clinical translation of nanomedicine are multiple
and complex. Among them are: (i) lack of education in business man-
agement, especially at the academic level, (ii) difficulties in performing
the pre-clinical characterization and safety assessment from early
stages, due to lack of protocols and lack of access to characterization
facilities, (iii) difficulties in scale-up and GMP manufacturing and (iv)
uncertainty and fragmentation in the regulatory framework, especially
for the most complex borderline products that combining multiple
technologies [4,36].
The European Technology Platform on nanomedicine (ETPN) [2] is
a think tank created in 2005 and set up together with the European
Commission (E.C.) to address the application of nanotechnology in
healthcare. The ETPN believes that involving industry will accelerate
the development of promising ideas and provide the effective and safe
healthcare products that patients need. Today, it gathers more than 130
member institutions from 27 different countries, representing the whole
value chain of healthcare from academia, SMEs, industry, healthcare
providers to national associations, scientific societies and policy ma-
kers. The ETPN has supported strong and smart public funding of the
most promising R&D topics – “where Nanomedicine can bring some-
thing more” – through strategic inputs coming for all stakeholders,
towards the E.C. for the last fifteen years. Complementarily, the ETPN
acts also as a driving for force for industrialization of nanomedicine in
Europe since 2014, detecting the best innovations of the field and fa-
cilitating their transfer from innovative design to clinical development
through the nanomedicine Translation HUB, a global set of premium
Fig. 4. The Nanomedicine Translation Hub: Developed infrastructure to accelerate the development of the best nanomedicine projects from innovative design to
clinical development. Translation HUB is not a linear process and innovative projects can benefit of each pillar independently.
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services, free-of-charge for the beneficiaries. This Hub is composed of
three main pillars, custom mentoring, product characterization and
GMP manufacturing, as represented in Fig. 4.
First, the HealthTech TAB (Translation Advisory Board) [37] is a
unique mentoring service in Europe, boosting selected HealthTech in-
ventions to transform them into successful businesses. It is funded and
managed by the NOBEL Project which is funded by the European
Commission under the Horizon 2020 research and innovation program.
The HealthTech TAB gives access to world-class expertise from former
managers from Pharma and Medtech industry, successful en-
trepreneurs, heads of innovation agencies, etc. Together, they offer
custom support to innovative project holders on specific issues for
which they usually lack skills: IP management, regulatory aspects,
business development, market access, scale-up, team building, fund
raising, etc. Application for the TAB is open to all: start-up, SMEs,
academics, individual entrepreneurs, industry, etc. This service is free-
of-charge for its beneficiaries, as a service funded by the E.C. through
the NOBEL Project. The HealthTech TAB has already supported +110
projects and helped its beneficiaries to raise +15 M€ in fundraising.
Another pillar of the Translation HUB is the European
Nanomedicine Characterization Laboratory (EUNCL) [38], a trans-
European, transdisciplinary characterization infrastructure founded in
2015, providing a comprehensive and integrated set of preclinical
characterization assays for the nanomedicine formulations, including
physical, chemical, in vitro and in vivo biological testing. EUNCL sup-
ports European stakeholders to advance the translation of their pro-
ducts into the clinic, e.g. advancing from TRL 3 to TRL4 or higher. Since
2015 EUNCL has operated thanks to E.C. H2020 funding and has sup-
ported more than 30 nanomedicine developers, including SMEs, big
pharma and universities, in the safety and quality assessment of their
formulation. More than 30 Standard Operating Procedures (SOP) have
been validated and shared with the community (http://www.euncl.eu/
about-us/assay-cascade/).
Finally, the Nanomedicine formulation could also benefit of one of
the three medium scale product lines regrouped in the third pillar
funded by Europe: Nanofacturing, Nanopilot and Maciviva. These have
been established for scaling up existing good manufacturing practice
(GMP) pilot lines to a medium-scale sustainable manufacturing process
for solid core nanopharmaceuticals and other medical nanobiomaterials
were funded. Interestingly, as a logical continuation of these first
publicly funded efforts to ensure easier scale-up of manufacturing for
nanomedicines in GMP conditions, a new industry offer provided by
contract development and manufacturing organizations has recently
appeared in Europe, proving both the high relevance and clear need of
this approach for technology providers in nanomedicine.
10. The need for a harmonized international regulatory
framework for regulating physical-chemical and biological
characterization of nanomedicines
Nanomedicines are not officially regulated differently from small
traditional drugs. To be successfully translated into the market FDA and
EMA both require that nanomedicines meet the same safety, efficacy
and pharmaceutical quality criteria applied to all drug products [39].
However, due to their unique and hybrid nature, the quality assessment
of nanomedicine formulations pose substantial analytical challenges
when compared to small molecular or biological drugs (e.g. antibodies).
In fact, in addition to the measurement of identity, strength, potency,
stability and impurities, bacterial endotoxins and bioburden of the
different chemical ingredients, additional physico-chemical properties
must be assessed for the final drug product (the final nanomedicine
formulation). These assessed properties include particle size, size dis-
tribution and polydispersity, surface charge, drug loading and drug
release profile, complex core-shell chemical and physical structure,
chemical and size stability during storage and when in contact with
biological media [40]. To add a layer of complexity, classical
characterization methods are often not applicable to nanomaterials.
Furthermore, more complex methodological approaches are needed in
order to understand how nanomedicine properties could impact their
safety and efficacy profiles (e.g. determined by their immunological
effects, biodistribution, pharmacokinetics, metabolism, and degrada-
tion profile) in order to determine the specific critical quality attributes
(CQAs) of each system.
The US National Cancer Institute Nanotechnology Characterization
Laboratory (NCI-NCL, ncl.cancer.gov/about-ncl) and the European
Nanomedicine Characterization Laboratory (EUNCL, euncl.eu) have
unbiasedly supported nanomedicine developers, by providing access to
their multidisciplinary characterization facilities, and also by pro-
moting knowledge and educational exchange within the community.
The two laboratories have jointly worked with other H2020 consortia
(e.g. REFINE and SAFE-N-MEDTECH), regulatory bodies (EMA and
FDA), metrology institutes and standard authorities (ASTM E56) in
order to develop new standards and to promote a harmonized approach
between Europe and the US. Unfortunately, despite their efforts, due to
the complexity to standardize characterization approaches on various
very specific nanomaterials, currently only a few standard methods for
nanomedicine characterization exist. Major gaps have been identified in
the lack of standardized methods to measure: (i) drug loading (free vs.
encapsulated drug), (ii) particle stability in plasma, including drug re-
lease kinetics, (iii) surface properties and surface interactions with the
biological environment and (iv) particle interactions with the immune
system [41–43].
In this context EMA has recently published a Regulatory Science
Strategic Reflection to 2025. One of five strategic goals and core re-
commendations proposed is “Enabling and leveraging research and in-
novation in regulatory science”, which includes to “Identify and access
the best expertise across Europe and internationally” and “Disseminate
and exchange knowledge, expertise and innovation across the network and
to its stakeholders”. ETPN is aware of the clear need to support the EMA
strategic aims to guarantee access to the best expertise across Europe
including infrastructure such as the EUNCL and novel initiatives such as
the Open Innovation Test Bed for nano-pharmaceuticals production to
support the development of a harmonized regulatory framework for
nanomedicine and borderline products combining different technolo-
gies in one cross-technological solution. In this context, ETPN will
support the continuation of the activities of the European
Nanomedicine Characterization Laboratory (EUNCL) as part of the
ETPN Translational Hub by reaching out for opportunities to pursue
continuous public funding which is needed to support developers to
bring their products to the market. Moreover, ETPN will support in-
ternational initiatives aiming to reduce the current fragmentation of the
standardization and the regulatory body landscape, e.g. by leading the
emerging EU-US Community of Research (CoR) in Nanomedicine, with
an international collaborative group called “EU-US Collaboratory”
under its umbrella. This initiative includes academia, R&D, regulators,
metrology and industrial experts, and has been created in order to
address the lack of validated harmonized and standardized physical-
chemical measurements of nanomedicines under the leadership of the
National Institute of Standard and Technology (NIST) from the US side
and the Joint Research Centre of the European Commission on the
European side [44].
11. Nanomedicine as a cross-sectoral and cross-technological
solution for healthcare
The ETPN has recently made efforts to strengthen the European
ecosystem for smart health technologies within the NOBEL project.
From precision engineering to smart connected HealthTech, and from
academic research to the clinic, NOBEL is creating a European
HealthTech ecosystem, for the convergence of nanomedicine with
photonics, robotics, biomaterials, smart systems, digital health and
textile. NOBEL has three main missions: (i) to build an ecosystem, as a
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unique meeting place for all stakeholders from academia to industry,
SMEs, clinicians and policy makers; (ii) to shape a common vision for
the future of HealthTech in Europe, the Continuum of Integrated Care,
incorporating the separate roadmaps of individual technologies, and
showing how concretely these medical technologies may improve the
whole journey of patients, for a more, preventive, predictive, perso-
nalized and sustainable medicine; (iii) to accelerate the transfer to
market of the most useful disruptive medical innovations, through the
funding of the HealthTech TAB.
By coordinating the NOBEL project since 2017, the ETPN pursues its
successful contribution to bring healthcare solutions faster to the
market and foster the strategic cross-sectorial approach and intensifies
crosstalk between different technology communities which is needed to
synchronize cross-technology innovation and developments necessary
to advance, e.g. functionalized surfaces for regenerative medicine ap-
proaches or smart biosensors to ensure distant monitoring of patients
and attenuate the acute phase of a disease. Nanomedicine as a hor-
izontal and essential complementary technology with broad applica-
tions in many medical fields of the Continuum of Integrated Care will
continue to be at the front of innovation in healthcare and the ETPN
will support and foster nanomedicine in this new vision. The ETPN is
strongly willing to keep on playing a key role in shaping the future of
health technologies in Europe, encouraging their synergy in a medical
problem solving approach rather than a techno-push approach, for
more preventive, patient-centered and sustainable health care. Indeed,
patients, and citizens in general, do not care about technology for the
sake of it. They care about quality of life.
12. Conclusions
From an ETPN perspective, nanomedicine unquestionably makes a
difference for patients. Even if we agree with Prof. Park that nanome-
dicine was overpromoted a few years ago as an immediate revolution
and several promises of nanomedicine are still not achieved, we are
entering a new period turning from academic development to proven
clinical value. We need to be constructive in our approach and focus on
the gaps to fill to accelerate nanomedicine translation into a more
mature phase. The ETPN will continue to support nanomedicine de-
velopment using its different platforms towards the integration of
knowledge, communication, and cooperation between different stake-
holders (including academia, industry, clinics, training patients/people
and related associations), providing instruments to support clinical
translation of new products and contributing to shape the nanomedi-
cine and smart health technologies landscape in Europe and in the
coming European research funding program Horizon Europe. ETPN is
also actively supporting formation of open-minded young researchers in
the field, which will be the future protagonists of ideas and innovations
for the sustainable development of nanomedicine. European support to
nanomedicine needs to remain a priority in the next Horizon Europe
program, so this technology can continue to contribute with cutting-
edge science and innovation as a provider of new solutions to tackle
complex medical challenges. The ETPN is therefore actively con-
tributing and will reinforce its participation in to future European in-
itiatives, including Europe's Beating Cancer plan, the Mission Cancer,
the Cluster Health, and the innovative European Partnership for
Innovative Health (Public Private Partnership) which is a new and
unique occasion to finally see the medtech, pharma and biotech in-
dustries work together in Europe. Nanomedicine will open new possi-
bilities to support the development of early diagnostic tools and better
treatments, in a new, more patient centered, era. But, nanomedicine
should not act as isolated technology and the ETPN will continue to be a
driving force in shaping a cross-technology environment, where nano-
medicine interacts with other technologies to design cross-technolo-
gical, multidisciplinary medical solutions for the benefit of the patients.
Declaration of Competing Interest
Matthieu GERMAIN and Agnes POTTIER are co-inventors of patent
applications related to Hensify product (Nanobiotix) described in this
article. Alexandre CECCALDI is employee of ETPN. The authors have no
other relevant affiliations or financial involvement with any organiza-
tion or entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript.
Credit authors statement
➢ Matthieu GERMAIN: Writing - Original Draft. Review & Editing
➢ Fanny CAPUTO: Writing - Original Draft. Review & Editing
➢ Su METCALFE: Writing - Original Draft. Review & Editing
➢ Giovanni TOSI: Writing - Original Draft. Review & Editing
➢ Kathleen SPRING: Writing - Original Draft. Review & Editing
➢ Andreas K. O. ÅSLUND: Writing - Original Draft. Review & Editing
➢ Agnes POTTIER: Review & Editing
➢ Raymond SCHIFFELERS: Review & Editing
➢ Alexandre CECCALDI: Review & Editing
➢ Ruth SCHMID: Review & Editing
References
[1] K. Park, The beginning of the end of the nanomedicine hype, J. Control. Release 305
(2019) 221–222, https://doi.org/10.1016/j.jconrel.2019.05.044.
[2] ETPN, www.etp-nanomedicine.eu.
[3] P. Grodzinski, NCI Centers of Cancer nanotechnology excellence (CCNEs) – a full
story to set the record straight, J. Control. Release 309 (2019) 341–342, https://doi.
org/10.1016/j.jconrel.2019.08.016.
[4] J.P. Martins, et al., The solid progress of nanomedicine, Drug Deliv. Transl. Res.
(2020), https://doi.org/10.1007/s13346-020-00743-2.
[5] The two directions of cancer nanomedicine, Nat. Nanotechnol. 14 (2019) 1083,
https://doi.org/10.1038/s41565-019-0597-5.
[6] S. Wilhelm, et al., Analysis of nanoparticle delivery to tumours, Nat. Rev. Mat. 1
(2016) 16014, , https://doi.org/10.1038/natrevmats.2016.14.
[7] S.E. McNeil, Evaluation of nanomedicines: stick to the basics, Nature Reviews
Materials 1 (2016) 16073, , https://doi.org/10.1038/natrevmats.2016.73.
[8] A.C. Anselmo, S. Mitragotri, Nanoparticles in the clinic: an update, Bioeng. &
Transl. Med. 4 (2019) e10143, , https://doi.org/10.1002/btm2.10143.
[9] M.R.C. Marques, et al., Nanomedicines - tiny particles and big challenges, Adv. Drug
Deliv. Rev. 151-152 (2019) 23–43, https://doi.org/10.1016/j.addr.2019.06.003.
[10] V. Weissig, T.K. Pettinger, N. Murdock, Nanopharmaceuticals (part 1): products on
the market, Int. J. Nanomedicine 9 (2014) 4357–4373, https://doi.org/10.2147/
IJN.S46900.
[11] A.C. Krauss, et al., FDA approval summary: (Daunorubicin and Cytarabine) lipo-
some for injection for the treatment of adults with high-risk acute myeloid
Leukemia, Clin. Cancer Res. 25 (2019) 2685, https://doi.org/10.1158/1078-0432.
CCR-18-2990.
[12] D. Adams, et al., Patisiran, an RNAi therapeutic, for hereditary Transthyretin
amyloidosis, N. Engl. J. Med. 379 (2018) 11–21, https://doi.org/10.1056/
NEJMoa1716153.
[13] B.E. Givens, Y.W. Naguib, S.M. Geary, E.J. Devor, A.K. Salem, Nanoparticle-based
delivery of CRISPR/Cas9 genome-editing therapeutics, AAPS J. 20 (2018) 108,
https://doi.org/10.1208/s12248-018-0267-9.
[14] S. Bonvalot, et al., NBTXR3, a first-in-class radioenhancer hafnium oxide nano-
particle, plus radiotherapy versus radiotherapy alone in patients with locally ad-
vanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2&#x2013;3, ran-
domised, controlled trial, Lancet Oncol. 20 (2019) 1148–1159, https://doi.org/10.
1016/S1470-2045(19)30326-2.
[15] U. Bulbake, S. Doppalapudi, N. Kommineni, W. Khan, Liposomal formulations in
clinical use: an updated review, Pharmaceutics 9 (2017) 12, https://doi.org/10.
3390/pharmaceutics9020012.
[16] N.M. Bressler, S.B. Bressler, Photodynamic therapy with Verteporfin (Visudyne):
impact on ophthalmology and visual sciences, Invest. Ophthalmol. Vis. Sci. 41
(2000) 624–628.
[17] T. Meng, V. Kulkarni, R. Simmers, V. Brar, Q. Xu, Therapeutic implications of na-
nomedicine for ocular drug delivery, Drug Discov. Today 24 (2019) 1524–1538,
https://doi.org/10.1016/j.drudis.2019.05.006.
[18] M. Douek, et al., Sentinel node biopsy using a magnetic tracer versus standard
technique: the SentiMAG multicentre trial, Ann. Surg. Oncol. 21 (2014) 1237–1245,
https://doi.org/10.1245/s10434-013-3379-6.
[19] C.E. Swenson, et al., Increased duration of heating boosts local drug deposition
during radiofrequency ablation in combination with thermally sensitive liposomes
(ThermoDox) in a porcine model, PLoS One 10 (2015) e0139752-e0139752, ,
https://doi.org/10.1371/journal.pone.0139752.
[20] L. Jena, E. McErlean, H. McCarthy, Delivery across the blood-brain barrier: nano-
medicine for glioblastoma multiforme, Drug Deliv. Transl. Res. 10 (2020) 304–318,
https://doi.org/10.1007/s13346-019-00679-2.
M. Germain, et al. Journal of Controlled Release 326 (2020) 164–171
170
[21] M. Valenza, et al., Cholesterol-loaded nanoparticles ameliorate synaptic and cog-
nitive function in Huntington’s disease mice, EMBO Mol Med 7 (2015) 1547–1564,
https://doi.org/10.15252/emmm.201505413.
[22] S. Tiwari, V. Atluri, A. Kaushik, A. Yndart, M. Nair, Alzheimer’s disease: patho-
genesis, diagnostics, and therapeutics, Int. J. Nanomedicine 14 (2019) 5541–5554,
https://doi.org/10.2147/IJN.S200490.
[23] A. Vilella, et al., Reduced plaque size and inflammation in the APP23 mouse model
for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS
targeted zinc delivery, J. Trace Elem. Med. Biol. 49 (2018) 210–221, https://doi.
org/10.1016/j.jtemb.2017.12.006.
[24] S.M. Metcalfe, S. Bickerton, T. Neurodegenerative Disease Fahmy, A perspective on
cell-based therapy in the new era of cell-free Nano-therapy, Curr. Pharm. Des. 23
(2017) 776–783, https://doi.org/10.2174/1381612822666161206141744.
[25] M. Salvalaio, et al., Targeted polymeric nanoparticles for brain delivery of high
molecular weight molecules in Lysosomal storage disorders, PLoS One 11 (2016),
https://doi.org/10.1371/journal.pone.0156452 e0156452-e0156452.
[26] J.T. Duskey, et al., In International Review of Neurobiology Vol. 137 (Eds Hari S.
Sharma & Aruna Sharma) 1–28, Academic Press, 2017.
[27] L. Rigon, et al., Targeting brain disease in MPSII: preclinical evaluation of IDS-
loaded PLGA nanoparticles, Int. J. Mol. Sci. 20 (2014), https://doi.org/10.3390/
ijms20082014 (2019).
[28] S. Mizrahy, A. Gutkin, P. Decuzzi, D. Peer, Targeting central nervous system
pathologies with nanomedicines, J. Drug Target. 27 (2019) 542–554, https://doi.
org/10.1080/1061186X.2018.1533556.
[29] C. Paviolo, P.R. Stoddart, Gold nanoparticles for modulating neuronal behavior,
Nanomaterials (Basel) 7 (2017) 92, https://doi.org/10.3390/nano7040092.
[30] A. Munawar, et al., Nanosensors for diagnosis with optical, electric and mechanical
transducers, RSC Adv. 9 (2019) 6793–6803, https://doi.org/10.1039/
C8RA10144B.
[31] N.P. Suh, Principles of Design, Oxford University Press (NY), 1990.
[32] M. Germain, et al., Priming the body to receive the therapeutic agent to redefine
treatment benefit/risk profile, Sci. Rep. 8 (2018) 4797, , https://doi.org/10.1038/
s41598-018-23140-9.
[33] H. He, L. Liu, E.E. Morin, M. Liu, A. Schwendeman, Survey of clinical translation of
Cancer Nanomedicines—lessons learned from successes and failures, Acc. Chem.
Res. 52 (2019) 2445–2461, https://doi.org/10.1021/acs.accounts.9b00228.
[34] C.H. Wong, K.W. Siah, A.W. Lo, Estimation of clinical trial success rates and related
parameters, Biostatistics 20 (2018) 273–286, https://doi.org/10.1093/
biostatistics/kxx069.
[35] C.L. Ventola, Progress in Nanomedicine: approved and investigational Nanodrugs, P
T 42 (2017) 742–755.
[36] J.J. Richardson, F. Caruso, Nanomedicine toward 2040, Nano Lett. 20 (2020)
1481–1482, https://doi.org/10.1021/acs.nanolett.0c00620.
[37] TAB, h, www.healthtech-tab.eu.
[38] EU-NCL, www.euncl.eu.
[39] K.M. Tyner, et al., Product quality for nanomaterials: current U.S. experience and
perspective, WIREs Nanomedicine and Nanobiotechnology 7 (2015) 640–654,
https://doi.org/10.1002/wnan.1338.
[40] FDA, Drug Products, Including Biological Products, that Contain Nanomaterials -
Guidance for Industry, https://www.fda.gov/regulatory-information/search-fda-
guidance-documents/drug-products-including-biological-products-contain-
nanomaterials-guidance-industry, (2017).
[41] U. Food, D. Administration, Global Summit on Regulatory Science (GSRS16). Global
Summit on Regulatory Science1 (GSRS16) Nanotechnology Standards and Applications.
Bethesda, MD, USA, 7–9, (2016).
[42] H. Box, et al., the REFINE white paper: Anticipation of regulatory needs for na-
notechnology-enabled health products EU commission, (2019).
[43] S. Bremer-Hoffmann, B. Halamoda-Kenzaoui, S.E. Borgos, Identification of reg-
ulatory needs for nanomedicines, J. Interdisciplinary Nanomed. 3 (2018) 4–15,
https://doi.org/10.1002/jin2.34.
[44] S. Gioria, F. Caputo, D. Mehn, Nano-enabled medicinal products: time for an in-
ternational advanced community? Nanomedicine 14 (2019) 1787–1790, https://
doi.org/10.2217/nnm-2019-0173.
M. Germain, et al. Journal of Controlled Release 326 (2020) 164–171
171
